HBOToday.com
Menu
HBOToday Editorial

Oxygen Was Said to Feed Tumours. A New Review Argues Malignancy Was Never a Reason to Refuse the Chamber.

A 2026 review in Frontiers in Aging argues that active malignancy is not a valid contraindication to hyperbaric oxygen, resting the case on 19 randomised trials. Those are the same 19 trials a Cochrane review used to record more severe radiation injury — and to warn that the benefits may depend on abandoned radiation schedules.

radiation-injury evidence-review research-study fda-regulation safety-risks insurance-coverage
Microscopy-style illustration of a crowded cell field over a deep indigo and teal ground: pale round cells with dark nuclei packed brightest at the top left and centre, the frame falling into shadow at the lower right, with small warm amber-stained structures scattered along the right side

Decades of hyperbaric practice have been shaped by a hypothesis that the trial record never set out to test: that filling a chamber with pressurised oxygen might feed a tumour rather than starve it. The review published on 5 November in Frontiers in Aging opens by naming that hypothesis. For decades, its authors write, the use of hyperbaric oxygen in oncology “has been constrained by theoretical concerns that hyperoxia might act as an unintended proliferative accelerator or tumor ‘fertilizer.’”

Avishai Abrahami, who works at WIX in Tel Aviv, and Shai Efrati, who directs the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, then set out to close the argument. They ask whether hyperbaric oxygen is safe in cancer patients, why its effects diverge between healthy and malignant tissue, and how it might be combined with oncology. The answer to the first question is one sentence. “Active or historical malignancy is not a valid contraindication for hyperbaric oxygen intervention.”

That sentence is not a claim that hyperbaric oxygen treats cancer. It is a claim that a fear which shaped years of gatekeeping was never grounded in evidence — and the strength of it depends entirely on what the authors counted.

What the review counted

The review reports more than 38 independent human clinical reports published since 1970, all finding “no association with tumor growth, recurrence, or metastasis,” reinforced by 19 randomised trials covering 1,103 tumour-bearing patients. On that corpus the authors run a power analysis and conclude that the probability of a genuine, undetected oncological hazard is less than 1 × 10⁻¹¹.

The numbers are more familiar than the framing suggests. A Cochrane review published in 2018 on hyperbaric oxygenation for tumour sensitisation to radiotherapy included 19 trials with 2,286 participants — 1,103 allocated to hyperbaric arms and 1,153 to control. The 1,103 in the new review is the hyperbaric half of that same corpus. It is not a new safety dataset. It is the radiotherapy-sensitisation literature, read again.

That distinction governs what the calculation can carry. Those trials enrolled patients with tumours because the hypothesis under test was that hypoxic tumours resist radiation and hyperbaric oxygen might overcome the resistance. None of them was designed as a safety study of tumour promotion: they were efficacy trials of radiosensitisation, with endpoints built around mortality, local control and recurrence, and populations dominated by head and neck, cervical and bladder cancer. A power analysis bounds a hazard only if it assumes the hazard would have declared itself in the endpoints that were collected. The authors treat that assumption as sound. A reader is entitled to treat it as the load-bearing assumption it is. The paper is also a review rather than a meta-analysis, so the 38 reports and the calculation are the authors’ own construction from the literature they selected.

The same nineteen trials, read by Cochrane

Which makes the Cochrane review the essential companion document, because it read the identical trials to answer a different question and reported a different headline.

For head and neck cancer, hyperbaric oxygen with radiotherapy reduced the risk of dying at one year (risk ratio 0.83, 95% confidence interval 0.70 to 0.98; number needed to treat 11) and at five years (0.82, 0.69 to 0.98). Local recurrence fell at one year (0.66, 0.56 to 0.78) and at five (0.77, 0.62 to 0.95), and local control immediately after irradiation improved (0.58, 0.39 to 0.85). For carcinoma of the uterine cervix the same review found no clear mortality benefit at one or five years and no clear effect on recurrence or metastases. Bladder cancer produced no clear benefit either.

The harms are the part that travelled into practice and then out of it. Across all cancer types combined, severe radiation tissue injury during treatment was more common with hyperbaric oxygen (risk ratio 2.35, 1.66 to 3.33), rising to 2.64 in the head and neck trials, and oxygen-toxic seizures were more frequent (6.76, 1.16 to 39.31). The reviewers’ conclusion was narrow: “These benefits may only occur with unusual fractionation schemes,” and, given the methodological inadequacies of the included studies, “our results demand a cautious interpretation.”

Both readings can be true at once. More normal-tissue injury and no tumour acceleration are compatible findings, and the new review says as much: it attributes the toxicity of the 1970s trials to altered fractionation, crude radiation fields and long pressure exposures, and notes that modern practice delivers radiation in the ten to fifteen minutes after decompression. What cannot be said is that a corpus which failed to detect tumour promotion was built to detect it.

Where the mechanism meets its own counter-example

The mechanistic case is the most elegant part of the paper and the most fragile.

Malignant cells, it argues, run on the Warburg phenotype with structurally degraded mitochondria — cristolysis is the term used — and therefore hold a compressed redox margin. Healthy cells answer an oxygen surge by up-regulating antioxidant enzymes. Tumour cells cannot. Add the destabilisation of HIF-1α, the suppression of glycolytic enzymes including hexokinase-2, PFK-1, PKM2 and lactate dehydrogenase, and the reversal of epithelial-to-mesenchymal transition, and hyperbaric oxygen becomes a selective metabolic stress rather than a growth signal.

Then there is the experiment pointing the other way. In 2025 a group at Chongqing General Hospital reported in Frontiers in Molecular Neuroscience that hyperbaric oxygen suppressed HIF1α, HIF2α and the drug-efflux transporter ABCG2 in glioblastoma cells — and that proliferation increased, alongside improved chemosensitivity. The paper’s own conclusion states both. A mechanism that predicts apoptosis produced, in that model, more cells and a better drug response.

A second review, published in Biology in September by a group from Izmir and Muğla, maps the same terrain and reaches a more guarded verdict. Preclinical and clinical evidence “does not support the historical assumption that HBOT universally accelerates tumor growth, recurrence, or metastasis,” it concludes, but “current evidence is also insufficient to support HBOT as a broadly applicable standalone anticancer therapy.” Its strongest clinical signal is late radiation-induced normal-tissue injury, “particularly radiation cystitis.” Its assessment of direct antitumour activity and sensitisation is that the evidence “remains predominantly preclinical and context-dependent,” and it notes plainly that “other models demonstrate increased proliferation or vascular responses.”

That is the honest state of the mechanism: a plausible, partly supported account of tissue selectivity, with published counter-examples in the same preclinical literature.

The real-world cohorts are the quiet part

Where the safety question actually gets answered is in the retrospective data the review cites without dwelling on them.

The strongest is a Taiwanese study published in Undersea and Hyperbaric Medicine in 2025. Hsieh and colleagues took the National Health Insurance Research Database from 2011 to 2019, identified 6,297 oral cancer patients who had all undergone tumour resection and radiotherapy, and separated the 254 who received hyperbaric oxygen for osteoradionecrosis from the rest. They matched on propensity scores, then used a time-dependent Cox model — the standard defence against immortal time bias, the error that makes any treatment given to survivors look protective. On second primary cancer, disease-specific mortality and all-cause mortality, the hazard ratios showed no statistically significant difference.

A smaller Turkish series, published in Medicina in 2025, followed 45 patients with solid tumours through a median of 27 sessions and a median of 783 days. Recurrence occurred in 8.7 percent, and there was no significant correlation between the number of sessions and either metastasis (p = 0.213) or mortality (p = 0.881).

These studies speak most directly to the clinical question, and both are retrospective. Neither was designed to detect a modest increase in recurrence, and both examined patients who were largely in remission or had treated disease. The trial that would settle it — a randomised cohort with recurrence as a prespecified endpoint — has not been run.

What the payment system already decided

Long before this review, the reimbursement system had resolved the practical version of the question in favour of treating cancer patients.

Medicare’s national coverage determination 20.29, effective 3 April 2017, limits hyperbaric oxygen to fifteen named conditions. Two of them are “osteoradionecrosis as an adjunct to conventional treatment” and “soft tissue radionecrosis as an adjunct to conventional treatment,” which means the programme already pays for chamber time in people who have had cancer, sometimes with cancer still present. The same document closes with a line that reads like the answer to a different question: “All other indications not specified under §270.4(A) are not covered under the Medicare program.”

The Undersea and Hyperbaric Medical Society’s fifteenth-edition list runs to fifteen entries, and malignancy is not one of them. Yet the question is not foreign to the society’s own literature: the chapter on delayed radiation injury opens by announcing that it will discuss “the effects of hyperbaric oxygen on cancer growth.”

The FDA’s position is the most often quoted and the least often read in full. The agency’s consumer update on the subject has been taken down from fda.gov; an archived copy, with content current as of 26 July 2021, states that “HBOT devices are not proven to cure cancer, Lyme disease, autism or Alzheimer’s disease,” lists thirteen cleared uses from air and gas embolism to non-healing diabetic foot ulcers, and adds that the agency “has not cleared or authorized the use of any HBOT device to treat COVID-19 or any conditions beyond those listed above.”

What the agency has said more recently is about hardware, not oncology. A provider letter dated 25 August 2025 reports fires in hyperbaric devices “that resulted in serious injuries and deaths,” states that “the root cause of these events is not known,” describes serious adverse events as rare, and issues eleven recommendations covering training, supervision for the duration of treatment, grounding, prohibited electrical and static-generating items, and hyperbaric-compatible clothing. For a cancer patient inside a chamber, that list describes the risk that is actually documented.

What this changes at the chamber door

For a clinician the review supplies something useful and overdue: a citable answer to the intake question. Refusing a chamber to a patient with a history of cancer who needs it for a cleared indication — osteoradionecrosis, a compromised flap after reconstruction, radiation cystitis — is not supported by the evidence, and the paper assembles the case for saying so out loud.

What it does not do is turn hyperbaric oxygen into an oncology drug. The synergy claim rests on the same head and neck trials Cochrane reviewed, whose benefits those reviewers tie to fractionation schemes no longer in use, and the modern protocol of irradiating minutes after decompression has not been tested at that scale. The paper’s own combination agenda — immunotherapy, chemotherapy, ketogenic metabolic therapy — is a research programme, not a treatment plan.

Two disclosures belong in the same paragraph as the argument. Efrati is head of the medical advisory board and a shareholder of AVIV Scientific; Abrahami is employed by WIX. The paper declares that no financial support was received and lists both affiliations openly.

The gap that remains is narrow and testable: a randomised cohort of cancer patients receiving hyperbaric oxygen for a cleared indication, with recurrence as a prespecified endpoint and follow-up long enough to see one. Until it exists, “not a valid contraindication” is a well-argued position supported by retrospective cohorts and by a re-analysis of trials built for another purpose. It is a strong argument. It is not yet a measurement.

Sources

  1. Abrahami A, Efrati S. Hyperbaric oxygen in cancer patients: a review of clinical safety, tissue selectivity, and therapeutic synergy. Front Aging. 2026;7:1961490.
  2. Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev. 2018;4:CD005007.
  3. Hsieh CH, Wen YW, Liao CT, Lee SR. Hyperbaric oxygen treatment after surgery and radiation for oral cancers does not increase the likelihood of a second primary development, nor reduce disease specific or overall survival. Undersea Hyperb Med. 2025;52(3):271-278.
  4. Demircan T, Ergözen S, Yıldırım B, Ünsal Hİ, Bilir A. Hyperbaric oxygen therapy in cancer: friend, foe, or context-dependent modulator? Biology (Basel). 2026;15(17):1512.
  5. Gong S, Wang P, Liao B, Zhao L, Wu N. Hyperbaric oxygen promotes both the proliferation and chemosensitization of glioblastoma cells by inhibiting HIF1α/HIF2α-ABCG2. Front Mol Neurosci. 2025;18:1584407.
  6. Canarslan Demir K, Avci AU, Ozgok Kangal MK, et al. Hyperbaric oxygen therapy for managing cancer treatment complications: a safety evaluation. Medicina (Kaunas). 2025;61(3):385.
  7. FDA. Follow instructions for safe use of hyperbaric oxygen therapy devices — letter to health care providers. 25 August 2025.
  8. FDA. Hyperbaric oxygen therapy: get the facts (consumer update, content current as of 26 July 2021; archived copy).
  9. CMS. National Coverage Determination 20.29: Hyperbaric Oxygen Therapy (effective 3 April 2017).
  10. Undersea and Hyperbaric Medical Society. Hyperbaric oxygen therapy indications, 15th edition.